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Abstract
Background: The aim of this study is to evaluate the safety and efficacy of bursectomy of D2 gastrectomy in terms
of postoperative complications and short-term survival outcomes.
Methods: From January 2012 to December 2013, data of 406 gastric cancer patients with advanced tumor stages
and who underwent D2 radical gastrectomy and were grouped according to whether bursectomy was performed
or not in West China Hospital, Sichuan University, were analyzed.
Results: Finally, 159 patients were in bursectomy group and 247 patients in non-bursectomy group. Surgical duration
was 260.1 ± 43.4 min in the bursectomy group, compared to 227.9 ± 48.6 min in the non-bursectomy group (p < 0.001).
The intraoperative blood loss was comparable between the bursectomy group and the non-bursectomy group (198.9
± 63.5 vs. 201.1 ± 53.7 ml, p = 0.729). Postoperative morbidity rate showed no significant difference between the two
groups, which were 23.3 % in the bursectomy group and 17.8 % in the non-bursectomy group, p = 0.179. The overall
survival outcomes of patients were compared between the two groups of all patients (p = 0.055): patients
who underwent distal gastrectomy (p = 0.129) and total gastrectomy (p = 0.016) and pT2-3 stage patients
(p = 0.117) and pT4a stage patients (p = 0.128). The multivariate survival analysis identified that bursectomy or
not, pT stage and pN stage were independent prognostic risk factors for the overall survival.
Conclusions: The bursectomy might increase the surgical duration when the D2 gastrectomy was done. Experienced
surgeons can perform it safely. However, for the survival benefits of bursectomy, long-term, large sample sized, and
high-quality randomized controlled trials are expected.
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Background
Gastric cancer is the second most common cause of
cancer-related death due to its malignant potential [1–3].
Owing to the absence of large sample size prospective ran-
domized control trials with long-term survival results,
there have been many disputes on the clinical use of bur-
sectomy with gastrectomy for advanced gastric cancer
patients. Bursectomy is mainly defined as a complete dis-
section of the peritoneal lining covering the pancreas and
the anterior plane of the transverse mesocolon and with
an omentectomy during gastrectomy [4, 5]. This surgical
technique has been developed as a part of radical gastrec-
tomy with the aim of removing the potential microscopic
tumor seeding since the 1960s in Japan and based on the
following oncological and anatomical theories [6–8]: (1)
prevents peritoneal recurrences by eliminating micro-
metastatic disease in the lesser sac of peritoneal cavity and
(2) complete resection of the subpyloric lymph nodes
(LNs). However, the therapeutic value of bursectomy is
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controversial because the survival benefit is uncertain.
One randomized controlled trial performed by the Osaka
University Clinical Research Group found that bursect-
omy may improve the survival outcomes in pT3-4 stages
patients and should not be dropped [9]. However, other
two retrospective studies indicated that there were no sur-
vival benefits for bursectomy when compared with non-
bursectomy for gastric cancer patients [10, 11]. According
to a recently meta-analysis that included one randomized
controlled trial (RCT) and three non-RCTs, Shen et al.
found that there was no survival benefits for the bursect-
omy when compared with non-bursectomy surgery for
gastric cancer patients and the bursectomy was not rec-
ommended as a routinely procedure for gastric cancer sur-
gery [12]. Meanwhile, the treatment guideline of Japanese
Gastric Cancer Association (JGCA) only recommended
that bursectomy can be selectively used according to the
specific tumor stage and location [13, 14].
Due to the high proportion of advanced stage patients
in China, we analyzed the clinicopathological data, the
postoperative complications and survival outcomes for
advanced gastric cancer patients who underwent D2 rad-
ical distal and total gastrectomy with or without bursect-
omy to report the initial experience of our center.
Methods
Ethical statement
The Ethics Committee of West China Hospital, Sichuan
University, approved this retrospective study. The partic-
ipants’ written consent were not obtained, but the pa-
tients’ records were anonymous to analysis.
Patients
From January 2012 to December 2013, those gastric can-
cer patients from the Department of Gastrointestinal Sur-
gery, West China Hospital, Sichuan University, were
included in this study based on the following criteria: (1)
histologically confirmed gastric adenocarcinoma; (2) pT2-
4, N0-3, and M0 stages according to the Japanese Classifi-
cation of Gastric Carcinoma [15]; (3) distal gastrectomy
and total gastrectomy by the conventional open method;
(4) D2 lymphadenectomy according to the Japanese gas-
tric cancer treatment guidelines [13]; and (5) curative re-
section without residual tumors (R0 resection). And those
patients with distant metastases or positive cytology
examination were excluded. Those patients underwent
preoperative adjuvant chemotherapy were excluded to
minimize the survival influence of it. Finally, the records
of the patients who fulfilled the inclusion and exclusion
criteria for this study were obtained and analyzed.
Bursectomy and operative procedure
All the gastric cancer patients included in this study had
undergone surgical treatments by well-trained surgeons
in the gastric cancer treatment team of our department.
Because this is not a randomized controlled study, pa-
tients who underwent bursectomy or non-bursectomy
surgery were intraoperatively decided by the chief sur-
geons. The surgical treatment principle was adopted by
the Japanese Gastric Cancer Treatment Guidelines which
was published by the JGCA [16]. For the resection pat-
terns, those advanced gastric cancer patients with tumors
located in the upper or middle third had total gastrec-
tomy. Patients with tumors located in the lower third of
the stomach and with lymph nodes metastasis in no. 1,
no. 2, and no. 4sb stations during the intraoperative frozen
section evaluation also underwent total gastrectomy. Only
lower third gastric cancers and distal gastrectomy can se-
cure the tumor-free radical resection and have distal gas-
trectomy. According to the guidelines of the JGCA, in
order to attain the complete dissection of subpyloric
lymph nodes, the right side of the anterior plane of the
transverse mesocolon and the pancreas was routinely
resected, which was partially bursectomy. Besides the right
side of the bursa omentalis, total bursectomy should be
with en bloc resection of the peritoneal lining of the bursa
omentalis (the anterior lobe of the transverse mesocolon
and the pancreas), and the anterior lobe of the transverse
mesocolon and the capsule of the pancreas should be dis-
sected as much as possible [10], which was defined as the
total bursectomy. Patients who underwent partial bursect-
omy (right side) were included in the non-bursectomy
group, and patients who underwent total bursectomy were
grouped in the bursectomy group. During the surgical
procedures, the exposure of the surgical field, appropriate
tension is essential to the success of completely removing
the anterior lobe of the transverse mesocolon and the cap-
sule of the pancreas (Fig. 1). Therefore, when the bursect-
omy is finished, only the posterior layer of the transverse
mesocolon remained and the anterior lobe of the trans-
verse mesocolon and the capsule of the pancreas were en-
tirely separated from the transverse mesocolon and the
pancreas (Fig. 2). Additional surgical procedures between
the two groups were similar. D2 lymphadenectomy was
carried out according to treatment guidelines published
by Japanese Gastric Cancer Association [13]. Roux-en-Y
esophagojejunostomy reconstructions were for total gas-
trectomy. And for distal gastrectomy, Billroth type I/II or
Roux-en-Y gastrojejunostomy reconstructions were per-
formed according to the tumor characteristics and others.
Clinicopathological characteristics
Clinicopathological characteristics, perioperative morbidity,
and mortality were analyzed. The cross-sectional location
and the longitudinal location of tumors were recorded ac-
cording to the standard of the Japanese Classification of
Gastric Carcinoma [15]. Lymph nodes were separately ex-
amined by the anatomical definitions of lymph node
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stations, according to the Japanese guidelines [13]. The
number of positive and examined lymph nodes of the no.
4d, no. 4sb, and no. 6 LNs were compared between the two
groups. The cancers were staged according to the Union
for International Cancer Control (UICC) tumor-node-
metastasis (TNM) system, 7th Edition [17]. Postoperative
mortality and morbidity were counted for 30 days or dur-
ing the same hospitalization. Specifically, the classification
of pancreatic fistula was according to the international
study group of pancreatic fistula classification [18]. The
grades of the postoperative complications by the Clavien–
Dindo classification of surgical complications between the
two groups were evaluated and compared [19].
Follow-up
The follow-up was performed by means of routinely out-
patient visit. Mail and telephone interviews were the
supplementary methods. The follow-up information was
Fig. 1 Removal of the anterior lobe of the transverse mesocolon. a The surgical plane of the removal of the anterior lobe of the transverse mesocolon
(front view). b The surgical plane of the removal of the anterior lobe of the transverse mesocolon (side view)
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updated until January 1, 2015. The follow-up rate, me-
dian follow-up duration (months), recurrence type, and
overall survival outcomes were analyzed in the study.
Recurrence types include the local-regional recurrence
(anastomotic recurrence) type, peritoneal seeding recur-
rence type, hematogenous recurrence (liver, pulmonary,
bone, et al.) type, distal lymph nodes (non-regional
lymph nodes) type, and multisite recurrence type. The
reasons for the patients lost to follow-up were predom-
inantly refusal of the outpatient visit or a change in the
telephone number and address.
Statistics
Statistical analysis was conducted using SPSS statistics
software, version 19.0 (SPSS, Chicago, Illinois, USA). For
the continuous variables with normal distribution, they
were analyzed by the one-way ANOVA test. Both the con-
tinuous variables without normal distribution and the
ranked variables were weighed by the Mann–Whitney U
test. The categorical variables were adopted with the Pear-
son’s chi-square test (or likelihood ratio). Survival out-
comes were reported to Kaplan–Merrier method, log-rank
test. Multivariate adjusted factor survival analysis was per-
formed using Cox proportional hazard modeling. Hazard
ratio (HR) and 95 % confidential interval (CI) were used
to present the results of the univariate and multivariate
survival analysis. Two-tailed p value of less than 0.05 was
regarded as statistically significant.
Results
Clinicopathological features
From January 2012 to December 2013, 406 gastric can-
cer patients were included in the final analysis, 159 of
whom in bursectomy group and 247 in non-bursectomy
group. Most of the clinicopathological characteristics
were comparable between the two groups, such as age,
gender, tumor size, and tumor locations, and as well as
tumor stages (Tables 1 and 2). Surgical duration was sig-
nificantly increased in the bursectomy group when com-
pared with the non-bursectomy group (260.1 ± 43.4 vs.
227.9 ± 48.6 min, p < 0.001, respectively). However, the
amount of blood loss was comparable between bursect-
omy group than the non-bursectomy group (198.9 ± 43.4
vs. 201.1 ± 53.7 ml, p = 0.729). Meanwhile, we found out
that more proportion of patients underwent total gas-
trectomy in bursectomy group than non-bursectomy
group (54.1 vs. 25.5 %, p < 0.001). Also, there existed dif-
ference in the longitudinal location of tumors (upper,
middle, lower) between the bursectomy and non-
bursectomy groups (39.0, 13.8, 47.2 % vs. 11.2, 18.2,
70.4 %, respectively, p < 0.001).
Lymph node status
Total number of examined LNs was significantly higher in
bursectomy group than non-bursectomy group (40.6 ± 17.5
vs. 25.4 ± 9.9, p < 0.001). Besides, the number of positive
lymph nodes was also higher in the bursectomy group
Fig. 2 Complete removal of the capsule of the pancreas and the anterior lobe of the transverse mesocolon
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than the non-bursectomy group (7.5 ± 8.7 vs. 5.9 ± 6.4,
p = 0.045). Comparison of the number of the positive
LNs and the number of examined LNs between the two
groups in no. 4d LNs, no. 4sb LNs, and no. 6 LNs were
listed in Table 2. The number of examined LNs was 4.9 ±
4.0 in no. 4d LNs of bursectomy group compared to 3.7 ±
2.7 of non-bursectomy group, p < 0.001. The number of ex-
amined LNs in no. 4SB LN and no. 6 LNs was similar be-
tween the two groups, p = 0.743 and p = 0.362, respectively.
Mortality and morbidity
There was no incidence of intraoperative mortality of pa-
tients in this study. The mean postoperative hospital stay
was 11.4 ± 4.4 days in bursectomy group and 11.4 ± 4.4 days
in non-bursectomy group (p = 0.850). Postoperative mor-
bidity rate was comparable between the bursectomy and
the non-bursectomy groups (26.4 vs. 17.8 %, p = 0.179).
Details of postoperative complications were listed in
Table 3. Reoperation was needed in five patients within
30 days of operation: three patients for abdominal cavity
hemorrhage and two patients for intra-abdominal ab-
scesses in bursectomy group and two patients for abdom-
inal cavity hemorrhage and another patient of intestinal
obstruction in non-bursectomy group. There was just one
hospital death; a patient in non-bursectomy group died of
postoperative acute myocardial infarction. All patients re-
covered well and successfully discharged from the hospital,
Table 1 Clinicopathological characteristics of the non-






N = 247 (%) N = 159 (%)
Age (years) 58.3 ± 12.2 57.3 ± 11.5 0.385
Gender 0.513
Male 160 (64.8) 108 (67.9)
Female 87 (35.2 51 (32.1)
Cross-sectional location 0.008
Lesser 124 (50.2) 101 (63.5)
Greater 15 (6.1) 11 (6.9)
Anterior 34 (13.8) 8 (5.0)
Posterior 40 (16.2) 15 (9.4)
Circumferential
involvement
34 (13.8) 24 (15.1)
Longitudinal location <0.001
U 28 (11.2) 62 (39.0)
M 45 (18.2) 22 (13.8)
L 174 (70.4) 75 (47.2)
Differentiation grade 0.328
Well-moderate 29 (11.7) 24 (15.1)
Poor-undifferentiated 218 (88.3) 135 (84.9)
Macroscopic type 0.307
Type 1 14 (5.7) 4 (2.5)
Type 2 99 (40.1) 75 (47.2)
Type 3 118 (47.8) 71 (44.7)
Type 4 16 (6.5) 9 (5.7)
Tumor size (cm) 5.7 ± 2.4 5.6 ± 2.3 0.537
Surgical duration (min) 227.9 ± 48.6 260.1 ± 43.4 <0.001
Blood loss (ml) 201.1 ± 53.7 198.9 ± 63.5 0.729
Resection patterns <0.001
DG 184 (74.5) 73 (45.9)
TG 63 (25.5) 86 (54.1)
Abbreviations: U upper, M middle, L lower, DG distal gastrectomy, TG
total gastrectomy







N = 247 (%) N = 159 (%)
T stage 0.136
T2 48 (19.4) 20 (12.6)
T3 45 (18.2) 37 (23.3)
T4 154 (62.3) 102 (64.2)
N stage 0.593
N0 60 (24.3) 38 (23.9)
N1 51 (20.6) 25 (15.7)
N2 43 (17.4) 28 (17.6)
N3 93 (37.7) 68 (42.8)
TNM stage 0.724
Ib 17 (6.9) 8 (5.0)
IIa 24 (9.7) 16 (10.1)
IIb 45 (18.2) 30 (18.9)
IIIa 47 (19.0) 22 (13.8)
IIIb 42 (17.0) 30 (18.9)
IIIc 72 (29.1) 53 (33.3)
No.4D LNs
Number of positive 0.7 ± 1.3 0.8 ± 1.8 0.675
Number of examined 3.7 ± 2.7 4.9 ± 4.0 0.001
No.4SB LNs
Number of positive 0.1 ± 0.5 0.1 ± 0.8 0.617
Number of examined 1.7 ± 2.2 1.6 ± 2.3 0.743
No.6 LNs
Number of positive 1.2 ± 2.0 0.9 ± 1.7 0.158
Number of examined 4.4 ± 3.4 4.8 ± 3.8 0.362
Total
Number of positive 5.9 ± 6.4 7.5 ± 8.7 0.045
Number of examined 25.4 ± 9.9 40.6 ± 17.5 <0.001
LNs lymph nodes
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including one patient in bursectomy group and one patient
in non-bursectomy group who had a duodenal stump fis-
tula with full drainage and effective nutrition support with
more than 30-day postoperative hospital stay. We also
compared the grades of postoperative complications ac-
cording to the Clavien–Dindo classification and found that
it was comparable between the two groups, p = 0.783 [19].
Survival outcomes
For the postoperative follow-up, there were 382 patients
with fully postoperative follow-up information and a 94.1 %
follow-up rate, 20 (2–35) months median follow-up dur-
ation. Survival benefits can be observed in bursectomy
group compared to non-bursectomy group, although with-
out significant difference, p= 0.055 (Fig. 3). In the univariate
survival analysis, the longitudinal location (p= 0.030),
macroscopic type (p = 0.027), tumor size (p = 0.002), re-
section patterns (p = 0.012), pT stage (p < 0.001), and pN
stage (p < 0.001) were prognostic risk factors for the overall
survival. And in the multivariate analysis, bursectomy
(without vs. with, p < 0.001), pT stage (pT2-3 stages vs. pT4
stage, p < 0.001), and pN stage (N0 vs. N3, p = 0.002) were
independent prognostic risk factors for the overall survival
(Table 4). Subgroup analyses were conducted in the resec-
tion patterns and pT stages. For those patients who under-
went distal gastrectomy, the survival outcome was
comparable between the two groups (p = 0.129), whereas
the bursectomy group had better prognosis of patients who
underwent total gastrectomy than patients in non-
bursectomy group (p = 0.016) (Fig. 4a, b). There is no sig-
nificant difference between the two groups for patients with
pT2-3 stages (p = 0.117) and pT4 stages (p = 0.128) (Fig. 5a,
b). And for patients with pT4 stage, although there exist
differences in the survival curves, no significant differences
are shown for patients who underwent distal gastrectomy
(p = 0.154) and total gastrectomy (p = 0.160) (Fig. 6a, b)
Discussion
In the 1960s, bursectomy is seen as an essential component
of radical surgery for serosa-involved gastric adenocarcin-
omas in Japan. However, surgical safety and oncologic ben-
efits are necessary factors in order to make sure
bursectomy as a potential useful therapeutic procedure in
the gastric cancer surgery according to the viewpoints
today. By the results of the previous study, safety of bur-
sectomy with D2 lymphadenectomy strongly hinges on the
experience of surgeons [20]. With regard to the long-term
survival outcomes, there was only one RCT that suggested
that bursectomy had some survival benefits among the
serosa-positive (pT3–T4) patients and without significant
difference, the 3-year overall survival rate was 69.8 % for
the bursectomy patients, in contrast to 50.2 % for the non-
bursectomy group [9], and the 5-years follow-up results of
this study existed similar results [21]. On the other hand,
other studies had totally opposite results, and they did not
find survival benefits of bursectomy when compared with
non-bursectomy surgery [10–12]. Moreover, in China,
more than half of gastric cancer patients were with ad-
vanced stage tumors. Therefore, we assessed the outcomes
of advanced gastric cancer patients who underwent D2 gas-
trectomy with bursectomy or who are not in a single insti-
tute of China. In this study, we found that the postoperative
complications rate was comparable between patients with
or without bursectomy, and D2 gastrectomy with bursect-
omy had benefits in short-term overall survival outcomes
when compared with non-bursectomy gastrectomy, espe-
cially for patients who underwent total gastrectomy.
Bursectomy is a complicated and technique-dependent
procedure, which may increase the surgical duration and
account for more blood loss during the operations. The
previous Japanese randomized controlled trial found that
bursectomy was associated with an additional 27 min
surgical duration and an additional 125 ml intraoperative
blood loss compared with non-bursectomy [20]. And an-
other cohort study found that bursectomy procedure
was associated with an additional 41 min operation
Table 3 Short-term outcomes of the non-bursectomy group






N = 247 (%) N = 159 (%)
Postoperative hospital
stay (days)
11.4 ± 4.4 11.4 ± 4.4 0.850
Overall morbidity 44 (17.8) 37 (23.3) 0.179
PPCs 19 (43.18) 15 (40.5)
Pancreatic fistula 4 (9.1) 5 (13.5)
Gastroparesis 5 (11.4) 3 (8.1)
Intraperitoneal
hemorrhage
3 (6.8) 5 (13.5)
Anastomotic leakage 1 (2.3) 1 (2.7)
SSIs 3 (6.8) 1 (2.7)
Intraperitoneal infection 5 (11.4) 6 (16.2)
Postoperative ileus 3 (6.8) 1 (2.7)
Acute myocardial
infarction
1 (2.3) 0 (0)
Postoperative mortality
Classification of complicationsa 0.759
Grade I 21 (47.7) 16 (43.2)
Grade II 19 (43.2) 16 (43.2)
Grade III 2 (4.5) 3 (8.1)
Grade IV 1 (2.3) 2 (5.4)
Grade V 1 (2.3) 0 (0)
Abbreviations: PPCs postoperative pulmonary complications, SSIs, surgical
site infections
aThe Clavien–Dindo classification of surgical complications
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times and an additional 65 ml intraoperative blood loss
[22]. Also in our study, increasing of the surgical dur-
ation can be discovered in bursectomy group than the
non-bursectomy group. The extra time consuming of
the operations was mainly because of the dissection of
the anterior of mesocolon of transverse and capsule of
the pancreas. However, long surgical duration and high
intraoperative blood loss do not mean the unsafety of
the surgical bursectomy procedures although with the
potential injury of the vessels of the mesocolon of trans-
verse. Blouhos et al. [22] found that the postoperative
morbidity rate was 19.4 % for patients with bursectomy,
and Imamura et al. [20], in their study, presented that
the overall morbidity rate was 14.3 % for both the bur-
sectomy and non-bursectomy. In our study, the inci-
dence of postoperative complications was comparable
with the two groups (bursectomy group 23.3 % vs.
non-bursectomy group 17.8 %, p = 0.179). Meanwhile,
the grade of complications according to the Clavien–
Dindo surgical complications classification [19] be-
tween the two groups was also comparable (p = 0.759).
Therefore, despite the fact that the bursectomy is a
time-consuming procedure, the D2 lymphadenectomy
with gastrectomy plus bursectomy can be performed
safely in high-volume experienced centers or by expe-
rienced surgeons [9].
Of the postoperative complications, in details, gastro-
intestinal surgeons are most concerned about the possible
damage of the pancreas and potential trend increase the in-
cidence of pancreatic fistula formation and postoperative
intestinal obstruction. Injury to the pancreatic parenchyma
may occur when dissecting the pancreatic capsule and lead
to the probable incidence of pancreatic fistula. Previous
study reported that subclinical pancreatic fistula could
occur in up to 10 % of the patients with the resection of the
pancreatic capsule [23]. And on the other hand, Imamura
et al., in their study, observed that there was no difference
in the incidence of pancreatic fistulas and amylase levels in
the postoperative drainage fluid between the bursectomy
group and non-bursectomy group [20]. They concluded
that pancreatic fistula may not be caused by the dissection
of the pancreatic capsule but owing to the lymphadenec-
tomy of those lymph nodes adjacent to the pancreas paren-
chyma. Blouhos et al. reported that the incidence rate of
pancreatic fistula is only 4.2 % (3/72) [22]. Generally, the re-
section of the pancreatic capsule is experienced cumulative
procedures, and the experienced surgeons in an experi-
enced center can rarely induce injury to the pancreas and
reduce the potential incidence of pancreatic fistula [22].
Next, concerned postoperative adverse events are the
possibility of intra-abdominal adhesion formation and the
potential intra-abdominal intestinal adhesive obstruction.
Fig. 3 Survival curves among the bursectomy group and non-bursectomy group. There was no significant difference in survival between the two
groups (p = 0.055)
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For the gastrectomy with bursectomy, adhesions to the
mesocolon and pancreas may cause specific symptoms,
such as delayed gastric emptying, afferent loop syndrome,
or intestinal obstruction [20]. The early stage postoperative
intestinal obstruction usually occurs in about 1–2 weeks
after the operation. However, postoperative intestinal ob-
struction can occur at any point in time during the postop-
erative period. Therefore, short-term postoperative
observation is not enough to fully evaluate the incidence of
postoperative intestinal obstruction. Long-term follow-up
and careful observation in a large sample size cohort study
is expected to draw the conclusion about postoperative in-
testinal obstruction of bursectomy.
The most important purpose of total bursectomy is to
eliminate the cancer cells for the prevention of potential
peritoneal relapse and improve the survival outcomes.
However, evidence of survival outcomes decides whether
“bigger surgery is better.” For the tumor that penetrates the
serosa of the stomach, some surgeons hold the attitude that
bursectomy cannot eliminate all disseminated free cancer
cells because the bursa omentalis is not a closed space and
bursectomy is unlikely to improve overall survival in pa-
tients with subserosa or serosa invasive cancers [10]. Previ-
ous studies found that there was no statistical difference
between the two groups in overall survival, and the bursect-
omy procedure was not recommended as a routinely pro-
cedure [5, 10–12, 24]. However, we also noticed that the
interim analyses and the final reports of Osaka trial found
that bursectomy surgery had some survival advantages
in stage pT3-4 patients when compared with non-
bursectomy surgery regarding the recurrence rate, re-
currence type (peritoneal seeding recurrence) and the sur-
vival rates [9, 21]. Meanwhile, we noticed that there is no
statistical difference between the recurrence rate and recur-
rence type between the two groups (Additional file 1: Table
S1). Recurrence type is another important factor to evaluate
the survival benefits for different resection strategies. These
results maybe due to the short-term follow-up duration,
which may not completely present the potential recurrence
between two groups. There is no difference of survival out-
comes between the two groups, but the bursectomy group
had better curves than the non-bursectomy group (Fig. 1).
The following may be the reasons for these results: the bur-
sectomy may have some benefits in terms of prolonging the
patients’ survival outcomes, but because of the sample size
and limited follow-up duration result, the statistical differ-
ence did not appear. In view of these results, besides Japan
and Korea, advanced stage gastric cancer account for about
half of total gastric cancer patients [25–27], especially in
China [28]. Therefore, a well-designed large sample RCTs
with long-term study to find out the details operation indi-
cations of the bursectomy for advanced gastric cancer pa-
tients are expected.
Interestingly, we noticed that the number of harvested
lymph nodes was significantly higher in the bursectomy
group than the non-bursectomy group (40.6 ± 17.5 vs.
25.4 ± 9.9, respectively, p < 0.001). Meanwhile, the number
of positive lymph nodes was also higher in the bursectomy
group than the non-bursectomy group (7.5 ± 8.7 vs. 5.9 ±
6.4, respectively, p = 0.045). Lymph node dissection strat-
egy is one of the hottest topics regarding gastric cancer
surgery. On one hand, because of the limitation of the
retrospective study, the potential selection bias may be one
reason, which results to the different lymph node results
between the two groups. Although, we only include those
Table 4 The univariate and multivariate survival analysis of all
patients
p value* Multivariate
HR (95 % CI)
p value**
Age 0.753




Lesser vs. greater vs. anterior
vs. posterior vs. circumferential
involvement
Longitudinal location 0.030





Type 1–2 vs. Type 3–4
Tumor size 0.002
<5 cm vs. ≥5 cm
Resection patterns
DG vs. TG 0.012
Bursectomy 0.055 0.025
With vs. without 1:1.640
(1.064–2.528)
T stage <0.001 1














Abbreviations: U upper, M middle, L lower, DG distal gastrectomy, TG
total gastrectomy
*Log-rank test; **Cox hazard model
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patients who underwent surgical treatment by surgeons of
gastric cancer surgical treatment team in our department,
which aims to dimension the potential bias coming from
operators. On the other hand, Greece scholar Blouhos et al.
presented right side bursectomy as an access plane for
completely en bloc dissection of lymph nodes [29]. This
may be another reason for the different lymph node result
between the two groups. It is certain that both the West-
ern and Eastern guidelines recommended at least 16 lymph
nodes examined for gastric cancer surgery in the N stage de-
termination [30]. In our study, the non-bursectomy dis-
sected 25.4 ± 9.9 lymph nodes, which is higher than the
recommendation of the guidelines. Also, some study re-
ported that the number of lymph node dissection is closely
Fig. 4 Survival curves among the bursectomy group and non-bursectomy group for patients who underwent distal gastrectomy (a) and total
gastrectomy (b)
Fig. 5 Survival curves among the bursectomy group and non-bursectomy group for patients with pT2-3 (a) stages and pT4a stages (b)
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related with the prognosis of patients [31–34]. Previous
study identified that for stage N2–N3 gastric cancer pa-
tients, harvesting at least 25 lymph nodes may represent a
superior cutoff for radical gastrectomy and could yield better
survival outcomes [35]. Therefore, regardless of the fact that
there existed a significant difference in the number of lymph
nodes between the two groups, the number of examined
lymph nodes in non-bursectomy is higher than the require-
ments of the present gastric cancer classification.
Meanwhile, different from the previous study, we in-
cluded those patients who underwent total gastrectomy. Al-
though, the results of this study found that there was no
significant difference in the short-term survival outcomes
between bursectomy and non-bursectomy groups. For
those patients who underwent total gastrectomy, the sur-
vival benefit of the bursectomy has appeared. Note that
despite that there is no significant difference in survival out-
comes for distal gastrectomy patients or pT4 stage patients,
the survival curves had demonstrated the separated trend-
ing between the two surgical strategies. As the previous de-
scription, sample size and short-term follow-up duration
may be the reasons for these survival results. Also, upper
third gastric cancers usually had poor tumor characteristics
and survival outcomes than lower third gastric cancers
[36]. Besides, those lower third gastric cancers that under-
went total gastrectomy are generally due to the poor tumor
characteristics. These may be the main reasons why there
exists a statistical difference between the two groups in
total gastrectomy and not in distal gastrectomy. Despite the
fact that this study set ups subgroup analysis in the
resection patterns and conducts the multivariate survival
analysis which identified that bursectomy or not is one of
the independent prognostic risk factors, the potential selec-
tion bias of the retrospective study was existing and which
must be emphasized here again. Regardless of the fact that
previous and present evidence did not strongly prove that
the bursectomy should be routinely performed, this
technique-dependent procedure may be existing survival
benefits in gastric cancer patients with specific characteris-
tics, such as T stages, tumor locations, or other characteris-
tics. Thus, well-designed RCTs are expected to clear these.
Conclusions
As a highly technique-dependent procedure, bursectomy
resulted in longer surgical duration than non-bursectomy
surgery. Experienced surgeons could safely perform D2
gastrectomy with bursectomy and the postoperative com-
plications not increased. Whether the bursectomy has sur-
vival benefits for all or special characteristics gastric cancer
patient and surgical indications of bursectomy surgery is
pending.
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Fig. 6 Survival curves among the bursectomy group and non-bursectomy group for patients with pT4a stage who underwent distal gastrectomy
(a) and total gastrectomy (b)
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